Martin Reck, MD, PhD; Lung Clinic Grosshansdorf 5Live #ASCO20
3:43
Key insights on Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Non Small Cell Lung Cancer
Martin Reck, MD, PhD; Lung Clinic Grosshansdorf 5Live #ASCO20
Key insights on Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Non Small Cell Lung Cancer Similar Videos
Similar Videos
-
Suresh Ramalingam, MD, FACP, FASCO; Winship Cancer Institute of Emory University; 5Live; #IASLC21
9:26
-
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
5:10
-
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
